FONT-SIZE Plus   Neg

Forest Labs, Pierre Fabre Report Results In Phase III Trial Of Levomilnacipran

Forest Laboratories, Inc. (FRX) and Pierre Fabre Medicament announced positive top-line results in a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder, or MDD.

Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD versus placebo, as early as week one and at each subsequent visit as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated. Levomilnacipran was generally well-tolerated in this study. The premature discontinuation rates were 25 percent for levomilnacipran and 21 percent for placebo. The most common adverse events observed in the levomilnacipran group were nausea, dizziness and constipation.

Results from an additional placebo-controlled Phase III fixed-dose study are expected in Spring 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Railroad operator CSX Corp. (CSX), Tuesday reported a slight drop in profit for the third quarter, as revenues dropped 9 percent hurt largely by lower coal freight revenues. Nevertheless, earnings for the quarter trumped Wall Street estimates, while revenues fell short. Jacksonville, Florida-based... Intel Corp. (INTC), the world's biggest chipmaker, Tuesday reported a drop in profit for the third quarter, as personal computer sales continue to decline. Intel generates a chunk of its revenues by selling chips for computers, however, the company has been negatively impacted by slowing demand for... Earnings at banking giant JP Morgan Chase (JPM) jumped more than 20% compared to last year, despite a decline in revenue. The firm's bottom line received a boost from about $2 billion in tax benefits.
comments powered by Disqus
Follow RTT